Chilton Capital Management LLC Acquires 235,131 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Chilton Capital Management LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 125,738.5% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 235,318 shares of the biopharmaceutical company's stock after buying an additional 235,131 shares during the period. Chilton Capital Management LLC's holdings in Gilead Sciences were worth $26,367,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Norges Bank purchased a new stake in shares of Gilead Sciences during the fourth quarter worth about $1,789,254,000. FMR LLC increased its holdings in Gilead Sciences by 21.6% during the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock worth $3,724,306,000 after purchasing an additional 7,157,113 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Gilead Sciences by 13,891.1% in the 1st quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company's stock valued at $285,761,000 after purchasing an additional 2,532,070 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Gilead Sciences by 19.7% during the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock valued at $1,377,707,000 after buying an additional 2,458,954 shares during the last quarter. Finally, Royal Bank of Canada grew its position in shares of Gilead Sciences by 30.1% during the fourth quarter. Royal Bank of Canada now owns 8,678,751 shares of the biopharmaceutical company's stock worth $801,655,000 after buying an additional 2,005,863 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock traded up $0.03 during trading on Monday, reaching $111.78. The company's stock had a trading volume of 6,955,665 shares, compared to its average volume of 7,703,268. Gilead Sciences, Inc. has a one year low of $66.34 and a one year high of $119.96. The stock has a 50-day moving average price of $107.02 and a two-hundred day moving average price of $104.11. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16. The stock has a market capitalization of $139.05 billion, a P/E ratio of 23.53, a price-to-earnings-growth ratio of 0.72 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. During the same period in the prior year, the firm earned ($1.32) earnings per share. Gilead Sciences's revenue was down .3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.83%. The ex-dividend date was Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is 66.53%.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on GILD shares. Morgan Stanley raised their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. JPMorgan Chase & Co. lifted their target price on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Oppenheimer lowered their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. Finally, Cantor Fitzgerald initiated coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price for the company. Nine research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $110.55.

Insider Buying and Selling at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the sale, the insider directly owned 121,152 shares of the company's stock, valued at $13,026,263.04. The trade was a 18.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 30th. The stock was sold at an average price of $110.45, for a total transaction of $1,104,500.00. Following the transaction, the chief executive officer directly owned 615,725 shares in the company, valued at $68,006,826.25. The trade was a 1.60% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 58,500 shares of company stock valued at $6,340,745. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.